Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeurogesX Inc.

www.neurogesx.com

Latest From Boehringer Mannheim GMBH

The Lonely World of European Device Start-Ups

Because of a conservative clinical culture and a skittish venture community, medical-device company creation has lagged in Europe. The reasons for the lack of device company creation are several: a physician community that is not only not entrepreneurial, but often averse to capitalizing on commercial opportunities; a venture capital community unfamiliar with devices; and a lack of
Medical Device Europe

BioXell: A New Beginning for Italian Biotech

The creation of Roche spin-off BioXell may signal a change in Italy's hitherto unfriendly biotech environment. Yet much remains to be done.
BioPharmaceutical Europe

ISIS optronics GMVH

A device currently in development at ISIS optronics GMBH in Mannheim, Germany, could give dermatologists and cosmetic surgeons a new way to look at skin, and so help them tailor treatment to individual patients. The device might eventually prove useful for pre-screening pateints for skin diseases such as melanoma, a condition seen with increasing frequency around the glove.
Medical Device

Exit, Pursued By a Bear

The buzz of Phoenix '99: In the teeth of their own bear market, device companies are running for any exit they can find because, until recently, the favored exit strategies for small, private medical device companies have been fairly traditional--going public and/or being acquired by a larger firm. But given the dismal performance of small cap device companies recently, the public markets virtually closed down for product companies, leaving only the M&A route. Dealmaking has become more viable as big companies increasingly look to small ones for new products, while small firms gain access to distribution channels, creating a greater co-dependency between the two. In 1999, however, even the M&A door has slammed shut, leaving small companies looking for new financing and business models to deal with the current lack of exit options.
Medical Device Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NeurogesX Inc.
  • Senior Management
  • Stephen F Ghiglieri, EVP, COO & CFO
    Stephen J Peroutka, MD, PhD, EVP, CMO
  • Contact Info
  • NeurogesX Inc.
    Phone: (650) 358-3300
    999 Baker Way
    Ste. 200
    San Mateo, CA 94404
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register